Extreme adverse event classification establishes protocols for unprecedented, catastrophic reactions warranting immediate investigation and reporting. Spontaneous reporting captures unexpected severe events. Expedited regulatory notification communicates serious safety signals. Causality assessment determines relationship likelihood. Risk mitigation strategies address identified hazards.
Risk-benefit reassessment may warrant market withdrawal. Communication to healthcare providers highlights dangers. Patient notification enables informed decision-making. Regulatory actions range from labelling changes to removal. Post-incident monitoring prevents recurrence.
General Biopharmaceutical Concepts
Extreme Adverse Event Classification
Extreme Adverse Event Classification categorises exceptionally severe or uncommon adverse events to support safety evaluation and regulatory reporting.
Continue Exploring
Browse over 900 biopharmaceutical terms across biologics, ADCs, cell & gene therapy, CMC, clinical development and manufacturing.
Browse Glossary →